ViiV Healthcare is committed to the development of new molecules that target unmet medical needs in HIV. The treatment of children with HIV/AIDS remains a significant unmet medical need and there is a pressing need for new medicines to tackle problems such as drug resistance, complex treatment regimens, and side effects associated with current treatments.
Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.
The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) Partnership for Pediatric AIDS Treatment was launched in 2006. This public-private partnership includes innovator and generic pharmaceutical companies and multilateral organizations such as UNAIDS, WHO and UNICEF.
Johnson & Johnson supports the Nyumbani Children's Home which covers communities throughout Nairobi. The Children's Home serves as a home to nearly 100 abandoned or orphaned children with HIV/AIDS. The children receive holistic care antiretroviral therapy, psychological, academic and spiritual support.
Novartis is focusing on the development of a one-dose cure for P. falciparum, the most dangerous form of malaria, and a curative modality for P. vivax, the most frequent-occurring and widely distributed type of malaria.
Mothers 2 Mothers (M2M) provides education for South African HIV-positive pregnant women about how to prevent mother-to-child transmission of the disease and later mentor other HIV-positive pregnant women.
In support of the GAVI Alliance's mission of increasing children's access to vaccines and strengthening delivery systems in the world's poorest countries, the Merck Vaccine Network – Africa (MVN-A) program provides immunization program managers in Africa with hands-on training in vaccine management and immunization services.
